64th ASH Annual Meeting and Exposition: 901. Health Services and Quality—Non-Malignant Conditions: Cell Line Down! Optimizing Diagnosis and Management of Isolated Cytopenias

Symposia: Health Services and Quality—Non-Malignant Conditions Oral and Poster Abstracts
Oral

Bleeding and Clotting, Research, adult, Clinical Practice (Health Services and Quality), Clinical Research, health outcomes research, health disparities research, pediatric, Diseases, thrombocytopenias, Immune Disorders, neutropenia, real-world evidence, Study Population, Human

291-292 (Ernest N. Morial Convention Center)

Moderators:

Kathleen Overholt, MD, and Robert M Stern, MD,

Disclosures:

No relevant conflicts of interest to declare.

The diagnosis and management of disorders with single-lineage cytopenias can be clinically challenging. In this session, authors will present innovations in improving the diagnosis of thrombocytopenic disorders including thrombotic thrombocytopenic purpura (TTP), immune thrombocytopenia (ITP), and heparin-induced thrombocytopenia (HIT). Then, authors will present experience in the diagnosis and management of isolated neutropenia in pediatric patients and in those with typical neutrophil count with Fy(a-b-) status.

9:30 AM

499

Standardizing the Diagnostic and Therapeutic Approach to Newly Diagnosed Children with ITP: Prospective Data from the ITP Consortium of North America (ICON) Quality Improvement Initiative

Hannah Elkus, MD¹, Rachael F. Grace, MD², Taylah Buissereth³^*, Carolyn Bennett, MD⁴, Stacey Rifkin-Zenenberg, DO⁵, Elizabeth R Gunn, MD⁶, Jeffrey D. Lebensburger, DO, MSPH⁷, Pablo Angulo, DO⁸^*, Monica Davini, MD⁸^*, Alexander W. Rankin, MD⁹, Taizo A. Nakano, MD¹⁰, Corinna L. Schultz, MD¹¹, Ashley Pinchinat, MD¹²^*, Kirsty Hillier, MD¹² and Sherif M. Badawy, MD¹

¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL
²Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA
³Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA
⁴Children's Hospital of Atlanta, Emory University, Atlanta, GA
⁵Joseph M. Sanzari Children’s Hospital, Hackensack University Medical Center, Livingston, NJ
⁶University of Alabama at Birmingham, Birmingham, AL
⁷University of Alabama At Birmingham, Birmingham, AL
⁸Division of Pediatric Hematology Oncology, University of Arizona Department of Pediatrics, Tucson, AZ
⁹Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO
¹⁰Center for Cancer and Blood Disorders, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO
¹¹Center for Cancer and Blood Disorders, Nemours Children's Health, Wilmington, DE
¹²Department of Pediatrics, Division of Pediatric Hematology-Oncology, Hassenfeld Children’s Hospital at NYU Langone Health, NYU Grossman School of Medicine, New York, NY

9:45 AM

500

Rapid Diagnosis of Acute Thrombotic Thrombocytopenic Purpura (TTP) Using a New Fully Automated Chemiluminescent Assay for Adamts-13 Activity. Clinical Performance and Cost-Effectiveness Analysis

Pierre Toulon, MD, PhD¹, Ines Harzallah²^* and Axel Sudria¹^*

¹Hematology, Pasteur University Hospital, Nice, France
²Hematology, Emile Müller Regional Hospital, Mulhouse, France

10:00 AM

501

Implementation of Electronic Alerts to Improve Clinician Management of Heparin Induced Thrombocytopenia

Becky Zon, MD^1,2, Katelyn W. Sylvester, PharmD³^*, David Rubins, MD^2,3^*, Jessica Grandoni, PharmD³^*, Julie Kelly, PharmD³^*, Shreya Timilsina, PharmD³^*, Mark Akladious³^*, Rajesh Patel, MD MPH^2,4^* and Jean M. M Connors, MD^2,3

¹Dana-Farber Cancer Institute, Boston, MA
²Harvard Medical School, Boston, MA
³Brigham and Women's Hospital, Boston, MA
⁴Beth Israel Lahey Health, Boston, MA

10:15 AM

502

Rethinking the Gold Standard: Real-World Performance of the Serotonin Release Assay (SRA) and PF4-Dependent P-Selectin Expression Assay (PEA) in the Diagnosis of Heparin-Induced Thrombocytopenia (HIT)

Jackson Hoesley¹^*, Rance C Siniard, MD²^*, Laura J. Taylor, M.T.³^*, Cari Reed, MT³^*, Marisa B. Marques, M.D.⁴ and Jori E. May, MD⁵

¹University of Alabama at Birmingham Heersink School of Medicine, Hoover, AL
²Division of Laboratory Medicine, Department of Pathology, University of Alabama at Birmingham, Birmingham, AL
³Special Coagulation Laboratory, University of Alabama at Birmingham, Birmingham, AL
⁴Division of Laboratory Medicine, University of Alabama at Birmingham, Birmingham, AL
⁵Department of Medicine, Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL

10:30 AM

503

Incidence of Typical Neutrophil Count with Fy(a-b-) Status Among Hematology Referrals for Neutropenia at an Urban Safety-Net Hospital

Anya Parekh, MD, MPH¹^*, Adam Lerner, MD²^*, Reggie Thomasson, MD²^* and John Mark Sloan, MD²

¹Beth Israel Deaconess Medical Center, Boston, MA
²Boston Medical Center, Boston, MA

10:45 AM

504

Diagnosis and Management of Isolated Neutropenia: A Survey of Pediatric Hematologists Oncologists

Elizabeth R Gunn, MD¹, Jacquelyn M. Powers, MD², AKM Fazlur Rahman, PhD³^*, Christina J. Bemrich-Stolz, MD, MSPH⁴^*, Stephen Mennemeyer, PhD⁵^*, Jeffrey D. Lebensburger, DO, MSPH⁶ and Hope P. Wilson, MD⁷

¹University of Alabama at Birmingham, Birmingham, AL
²Department of Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine/ Texas Children's Hospital, Houston, TX
³Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL
⁴Univeristy of Alabama at Birmingham, Birmingham, AL
⁵School of Public Health, University of Alabama at Birmingham, Birmingham, AL
⁶Division of Pediatric Hematology Oncology, University of Alabama At Birmingham, Birmingham, AL
⁷Division of Pediatric Hematology Oncology, The University of Alabama at Birmingham, Birmingham, AL

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

901.O2.6 901. Health Services and Quality—Non-Malignant Conditions: Cell Line Down! Optimizing Diagnosis and Management of Isolated Cytopenias